A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

(2012) W. Eiermann et al.   ANNALS OF ONCOLOGY

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

(2012) Nathan W. D. Lamond et al.   BREAST CANCER RESEARCH AND TREATMENT

Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting

(2012) J. U. Blohmer et al.   JOURNAL OF MEDICAL ECONOMICS

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

(2011) J. Albanell et al.   ANNALS OF ONCOLOGY

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Spontaneous Regression of Follicular Dendritic Cell Sarcoma

(2011) Donne Bennett De Leon Caces et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2010) S. Aebi et al.   ANNALS OF ONCOLOGY

Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

(2010) Masahide Kondo et al.   BREAST CANCER RESEARCH AND TREATMENT

Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection

(2010) Shelly S. Lo et al.   JOURNAL OF CLINICAL ONCOLOGY

Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization

(2010) Shmuel H. Klang et al.   VALUE IN HEALTH

Health-state utility values in breast cancer

(2010) Tessa Peasgood et al.   Expert Review of Pharmacoeconomics & Outcomes Research

The total hospital and community UK costs of managing patients with relapsed breast cancer

(2009) R J Thomas et al.   BRITISH JOURNAL OF CANCER

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

(2009) Kathy S Albain et al.   LANCET ONCOLOGY

Predictors of return to work ten months after primary breast cancer surgery

(2008) Aina Johnsson et al.   ACTA ONCOLOGICA